Part-Time
Medical Research Assistant
Celerion
1,001-5,000 employees
Global CRO for early-phase development
Compensation Overview
$17.50/hr
Lincoln, NE, USA
In Person
Early weekday mornings (6a-10a) required; weekend availability required.
 Biology & Biotech (2) |
|---|
| , |
People at Celerion
People at Celerion who can refer or advise you
- High school diploma or General Educational Development certificate.
- Monitor activities of study participants, handle human biological samples and record data.
- Take vital signs, perform electrocardiograms, collect blood samples (phlebotomy), measure height and weight, and monitor meals.
- Post high school education in life sciences or medical training preferred.
- CPR certification preferred.
- Experience in accurate documentation of data preferred.
Celerion is a global contract research organization focused on early-phase drug development. It supports pharmaceutical and biotech clients with trial design, feasibility, project management, clinical and medical monitoring, bioanalytical sciences, and regulatory affairs, all conducted under contract. Its work hinges on metabolite profiling using high-resolution mass spectrometry to inform development decisions. With 40+ years of experience and a global, integrated service network, Celerion aims to help clients bring safe, effective treatments to patients faster by delivering rigorous, timely research.
Company Size
1,001-5,000
Company Stage
Acquired
Total Funding
N/A
Headquarters
Lincoln, Nebraska
Founded
2010
People at Celerion
People at Celerion who can refer or advise you
Simplify's Take
What believers are saying
- Zurich lab expansion in June 2026 adds gene therapy and immunogenicity testing capacity.
- THL Partners' 2026 majority investment accelerates global clinical and bioanalytical capability growth.
- Enhanced Labnotes software launched May 2025 improves large dataset handling and report speed.
What critics are saying
- THL's aggressive leverage forces pivot to low-margin bioanalysis, risking margin compression in 6–12 months.
- ICH M10 enforcement in 2026 requires revalidating 40% of assays, blocking submissions if delayed.
- IQVIA secured 12 GLP-1 contracts worth $220M, starving Celerion of its top growth segment.
What makes Celerion unique
- Celerion specializes in early-phase drug development with over 50 years of experience.
- Its expertise in HR-MS metabolite profiling using SCIEX TripleTOF® 6600+ sets industry standards.
- Integrated global bioanalytical labs in Lincoln, Zurich, and Belfast enable rapid sample management.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Flexible Work Hours
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 4%LINCOLN, Neb.; May 6, 2025 (Business Wire) – Celerion, a global leader in early clinical research and bioanalytical services, announced the launch of the latest version of Labnotes, its cutting-edge bioanalytical electronic laboratory notebook software elevating data handling and analysis capabilities for sponsors. The latest system enhancements streamline laboratory documentation and improve operational efficiency for users. The updated platform also offers advanced tools for handling and organizing large datasets, ensuring faster processing of reports and optimized database queries
Celerion launches enhanced version of labnotes bioanalytical data Management software.
Celerion was recognized as a CRO Leader in the quality, capabilities and reliability categories across two groups of respondents (small pharma and combined big and small pharma).
LINCOLN, Neb.--(BUSINESS WIRE)--Celerion, a leading clinical research organization, specializing in early clinical research and bioanalytical services, today announced the appointment of Jo Goodman as vice president of bioanalytical services in its Lincoln, Nebraska, laboratory. In her new role, Goodman will oversee the strategic direction and operational performance of the Lincoln bioanalytical laboratory, leveraging her extensive experience in pharmaceutical research and development to drive innovation and design and execute customized bioanalysis for clients’ needs. She will be responsible for delivering on Celerion’s bioanalytical promise of industry-leading science, stringent compliance, and speed of delivery. With over 29 years of experience in the pharmaceutical industry, Goodman brings a wealth of knowledge in regulated GxP and discovery bioanalysis for both in-house and outsourced activities. Prior to joining Celerion, she held positions of increasing responsibility at AstraZeneca, MedImmune, and GlaxoSmithKline. Additionally, Goodman is a recognized thought leader, having recently served as a member of the Expert Working Group (EWG) for ICH M10 Bioanalytical Guidance Development and is active in numerous non-profit industry consortia such as EBF, AAPS, and DMDG
Celerion announced the appointment of Jo Goodman as vice president of bioanalytical services in its Lincoln, Nebraska, laboratory.Post this